Press Releases May 4, 2026 08:30 AM

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Fortress Biotech CEO to Present at H.C. Wainwright Royalty Company Virtual Conference

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
FBIO

Fortress Biotech announced that its CEO, Lindsay A. Rosenwald, M.D., will participate in a fireside chat at the upcoming H.C. Wainwright 2nd Annual Royalty Company Virtual Conference. The company highlights its biopharmaceutical portfolio and strategic partnerships in advancing product opportunities across oncology, dermatology, and rare diseases.

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
FBIO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Fortress Biotech focuses on acquiring and advancing biopharmaceutical assets to generate long-term shareholder value through multiple revenue streams including product sales, equity holdings, dividends, and royalty income.
  • The company has a diverse portfolio covering oncology, dermatology, and rare diseases, with several marketed products and development programs managed through majority-owned and partnered entities.
  • Fortress Biotech maintains strategic collaborations with top-tier academic research institutions and biopharmaceutical companies, such as AstraZeneca and Dana-Farber Cancer Center, to maximize its product pipeline potential.

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, taking place on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 12:30pm ET.

To register for the conference, visit https://hcwevents.com/royalty-company-conference.

About Fortress Biotech 
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.

Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com  


Risks

  • Dependence on successful development and commercialization of pipeline products in competitive therapeutic areas like oncology and rare diseases, which face regulatory and clinical trial uncertainties.
  • Reliance on partnerships and collaborations for product advancement may pose risks if partner dynamics or external research results do not meet expectations.
  • The biopharmaceutical sector is subject to regulatory, reimbursement, and market acceptance risks, which could impact the company's financial performance and royalty income streams.

More from Press Releases

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026